Cyclohexane derivatives difunctionalised in 1,4 as ligands of 5T H1A receptors
    1.
    发明授权
    Cyclohexane derivatives difunctionalised in 1,4 as ligands of 5T H1A receptors 有权
    环己烷衍生物在1,4中作为5T H1A受体的配体双功能化

    公开(公告)号:US06191130B1

    公开(公告)日:2001-02-20

    申请号:US09529783

    申请日:2000-04-14

    IPC分类号: C07D25306

    摘要: The invention concerns novel cyclohexane derivatives difunctionalised in 1.4 of general formula (1) in which A represents a group such as (IIa) in which Ar itself represents an aromatic structure such as phenyl or pyrimidinyl optionally substituted by one or several groups such as C1-C3 alkyl, C1-C3 alkoxy, trifluoromethyl or halogen (IIb); B represents a heterocyclic group such as: 3,5-dioxo-(2H,4H)-1,2,4 triazine substituted in position 2 (IIIa); 3-oxo-(2H)-1,2,4 triazine substituted in position 5 (IIIb); 3,5-dioxo-6-amino-(2H,4H)-1,2,4-triazine (IIIc) in which R represents a C1-C3 alkyl group. The invention also concerns the salts of compounds of general formula I with pharmaceutically acceptable acids. It also concerns the various “cis” and “trans” isomers and the various enantiomers with asymmetric carbons.

    摘要翻译: 本发明涉及在1.4通式(1)中双官能化的新型环己烷衍生物,其中A代表其中Ar本身表示芳族结构的基团,例如苯基或嘧啶基,其任选被一个或多个基团取代,如C1- C3烷基,C1-C3烷氧基,三氟甲基或卤素(IIb); B表示杂环基,例如:位置2(IIIa)取代的3,5-二氧代 - (2H,4H)-1,2,4-三嗪; 在位置5(IIIb)取代的3-氧代 - (2H)-1,2,4-三嗪; 3,5-二氧代-6-氨基 - (2H,4H)-1,2,4-三嗪(IIIc),其中R表示C1-C3烷基。 本发明还涉及通式I的化合物与药学上可接受的酸的盐。 它还涉及各种“顺式”和“反式”异构体和具有不对称碳的各种对映异构体。

    3,5-dioxo-(2H,4H)-1,2,4-triazine derivatives as 5HT.sub.1A ligands
    2.
    发明授权
    3,5-dioxo-(2H,4H)-1,2,4-triazine derivatives as 5HT.sub.1A ligands 失效
    3,5-二氧代 - (2H,4H)-1,2,4-三嗪衍生物作为5HT1A配体

    公开(公告)号:US5591743A

    公开(公告)日:1997-01-07

    申请号:US578522

    申请日:1996-03-26

    CPC分类号: C07D253/075 C07D405/12

    摘要: A 3,5-dioxo-(2H,4H)-1,2,4-triazine compounds of formula I ##STR1## in which: R.sub.1 and R.sub.2, which are identical or different, represent hydrogen or C.sub.1 -C.sub.6 alkyl, n is 2 to 6, inclusive,A represents aryl piperazino II ##STR2## the Ar grouping representing phenyl, naphthyl, pyrimidyl, or pyridyl, unsubstituted or substituted by C.sub.1 -C.sub.3 alkyl, C.sub.1 -C.sub.3 alkoxy, hydroxy, trifluoromethyl, or halogen, or III benzodioxanyl-methyl-amino or pyridodioxanyl-methyl-amino ##STR3## in which R represents hydrogen or C.sub.1 -C.sub.3 alkyl and X represents a nitrogen or carbon atom, therapeutically-acceptable salts and enantiomers thereof, pharmaceutical compositions thereof, and method for treatment of diseases requiring a 5HT.sub.1A receptor agonist therewith.

    摘要翻译: PCT No.PCT / FR94 / 00772 Sec。 371日期:1996年3月26日 102(e)1996年3月26日PCT 1994年6月27日PCT公布。 第WO95 / 01965号公报 日期:1995年1月19日A式Ⅰ的3,5-二氧代 - (2H,4H)-1,2,4-三嗪化合物其中:R1和R2相同或不同,表示氢或C1 C 1-6烷基,n为2至6,包括端值,A表示芳基哌嗪基II代表苯基,萘基,嘧啶基或吡啶基的Ar基团,未取代或被C 1 -C 3烷基,C 1 -C 3烷氧基,羟基, 三氟甲基或卤素,或III苯并二恶烷基 - 甲基 - 氨基或吡啶并二恶烷基 - 甲基 - 氨基,其中R表示氢或C1-C3烷基,X表示氮或碳原子,其治疗上可接受的盐和对映体,药物 其组合物,以及治疗需要5HT1A受体激动剂的疾病的方法。

    3-oxo-2(H)-1,2,4-triazine derivatives as ligands of 5 HT1A receptors
    3.
    发明授权
    3-oxo-2(H)-1,2,4-triazine derivatives as ligands of 5 HT1A receptors 有权
    3-羟基-2(H)-1,2,4-三嗪衍生物作为5个HT1A受体的配体

    公开(公告)号:US06303603B1

    公开(公告)日:2001-10-16

    申请号:US09529728

    申请日:2000-04-14

    IPC分类号: A61K3153

    摘要: The invention concerns novel 3-oxo-(2H)-1,2,4-triazine derivatives of general formula (I) in which R1 represents: hydrogen, when A is an optionally substituted nitrogen atom; a linear or branched 1-C4 alkyl group; a C1-C4phenyl alkyl group, the phenyl ring being optionally substituted by one or several groups such as C1-C4 alkyl, C1-C3 alkoxy, halogen, trifluoromethyl. R2 represents: hydrogen; a linear or branched C1-C4 alkyl radical; a C1-C4 phenyl or phenylalkyl group, the phenyl ring being optionally substituted by one or several groups such as C1-C4 alkyl, C1-C3 alkoxy, halogen, trifluoromethyl. A represents an oxygen atom or a nitrogen atom optionally NR3 substituted. R3 represents hydrogen or a methyl group. B represents a group such as (IIa) in which Ar itself represents an aromatic structure such as phenyl, pyridyl or pyrimidyl, optionally substituted by one or several groups such as C1-C3 alkyl, C1-C3 alkoxy, hydroxy, trifluoromethyl or halogen and n can be whole numbers ranging between 3 and 5; (IIb) in which Ar is as defined in formula (IIa) and m can be a whole number ranging between 1 and 2; (IIc) in which R4 represents hydrogen or a C1-C3 alkyl group and n can be whole numbers ranging between 3 and 5.

    摘要翻译: 本发明涉及通式(I)的新的3-氧代 - (2H)-1,2,4-三嗪衍生物,其中当R1是任意取代的氮原子时,R 1表示:氢; 直链或支链的1-C4烷基; C1-C4苯基烷基,苯环任选被一个或多个基团取代,例如C 1 -C 4烷基,C 1 -C 3烷氧基,卤素,三氟甲基。 R2表示:氢; 直链或支链C 1 -C 4烷基; C 1 -C 4苯基或苯基烷基,苯环任选被一个或几个基团例如C 1 -C 4烷基,C 1 -C 3烷氧基,卤素,三氟甲基取代。 A表示氧原子或任选被NR 3取代的氮原子。 R3表示氢或甲基。 B表示其中Ar本身表示芳族结构的基团,例如苯基,吡啶基或嘧啶基,任选被一个或多个基团例如C 1 -C 3烷基,C 1 -C 3烷氧基,羟基,三氟甲基或卤素取代, n可以是3到5之间的整数; (IIb)其中Ar如式(IIa)中所定义,m可以是1和2之间的整数; (IIc)其中R4表示氢或C1-C3烷基,n可以是3至5的整数。

    3β-amino azabicyclooctane heteroaromatic amid derivatives preparation method and therapeutic uses thereof
    5.
    发明授权
    3β-amino azabicyclooctane heteroaromatic amid derivatives preparation method and therapeutic uses thereof 有权
    3β-氨基偶氮二异辛烷杂芳族衍生物的制备方法及其治疗用途

    公开(公告)号:US07456192B2

    公开(公告)日:2008-11-25

    申请号:US10494639

    申请日:2002-10-30

    CPC分类号: C07D491/04 C07D495/04

    摘要: The invention concerns compounds of general formula 1, wherein: A, B, D and E represent one or two nitrogen atoms, the others being carbon atoms; X represents a S or, a O, thereby forming a bicyclic fused heteroaromatic, such as thieno[2,3-b]pyridine, furo[2,3-b]pyridine, thieno[3,2-b]pyridine, furo[3,2-b]pyridine, thieno[2,3-b]pyrazine, furo[2,3-b]pyrazine, thieno[2,3-c]pyridine, furo[2,3-c]pyridine, thieno[3,2-c]pyridine and furo[3,2-c]pyridine; R1 represents a linear or branched C1-C6 alkoxy group, a linear or branched C1-C6 alkylthio group; R2 represents a linear, branched, cyclic C2-C8 group, a 2- or 3-thienylmethyl group, or a benzyl group optionally substituted by one or several halogens, F, Cl, Br, I, C1-C4alkyl, C1-C4 alkoxy, CF3, CN, NO2, OH; and their pharmaceutically acceptable salts. Said compounds are anti-dopaminergic agents.

    摘要翻译: 本发明涉及通式1的化合物,其中:A,B,D和E代表一个或两个氮原子,其余是碳原子; X表示S或O,由此形成双环稠合杂芳族化合物,例如噻吩并[2,3-b]吡啶,呋喃并[2,3-b]吡啶,噻吩并[3,2-b]吡啶,呋喃并[ 3,2-b]吡啶,噻吩并[2,3-b]吡嗪,呋喃并[2,3-b]吡嗪,噻吩并[2,3-c]吡啶,呋喃并[2,3-c]吡啶,噻吩并[ 3,2-c]吡啶和呋喃并[3,2-c]吡啶; R 1表示直链或支链C 1 -C 6烷氧基,直链或支链C 1 -C 6烷氧基,直链或支链C 1 -C 6 - 烷硫基 R 2表示直链,支链,环状C 2 -C 8亚烷基,2-或3-噻吩基甲基或任选被一个或多个卤素取代的苄基, F,Cl,Br,I,C 1 -C 4烷基,C 1 -C 4烷氧基, CF 3,CN,NO 2,OH; 及其药学上可接受的盐。 所述化合物是抗多巴胺能药。